Liaoning Chengda acquires the 772 equity of Chengd

2022-08-09
  • Detail

Liaoning Chengda acquires 7.72% equity of Chengda biology

on the evening of January 26, Liaoning Chengda announced that the seventh (Interim) meeting of the board of directors of the company passed a resolution on the acquisition of related party transactions, which mainly includes: 12 natural person shareholders intend to transfer 15.296.803 shares of all Chengda biology shares held by them to the core employees of Liaoning Chengda and Liaoning Chengda biology Co., Ltd. after the completion of this equity transfer

after the completion of this transaction, the shareholding ratio of Liaoning Chengda to Chengda biology will increase from 54.79% to 62.51%, which will improve the control right and investment income of Chengda biology

as of December 31, 2009, through the audit of Huapu Tianjian Certified Public Accountants (Beijing) Co., Ltd., the total assets of Chengda biological were 735304100 yuan, and the net assets were 587924600 yuan; In 2009, the sales revenue was 43239900 yuan, and the expansion of the utilization pattern of anti rust oil applied during packaging should be highly consistent with the strategic plan in the 10 fields of "made in China 2025", with a profit of 200136100 yuan

Liaoning Chengda also said that with its own advantages and the improvement of the national pharmacopoeia 2010 on the vaccine industry standards, Chengda biology is expected to maintain a good development trend in the next few years, especially the performance in 2010 will grow rapidly compared with that in 2009. This increase in the company's shareholding ratio will enable the company to share more of the future growth achievements of Chengda biology and obtain more investment income

about Chengda biology

"Chengda biology" was established in Shenyang in June 2002. It is a high-tech enterprise jointly established by Liaoning Chengda Co., Ltd. and Liaoning Biomedical Engineering Research Institute. In September, 2002, a land requisition of 40 mu was made in Hunnan New Area of Shenyang. With the assistance of experts from the World Health Organization (who) and FDA, a 5000m2 production workshop and 1500m2 ancillary facilities were built. In China, the bioreactor high-density microcarrier Vero cell culture technology and advanced equipment of Bari company of the United States were exclusively introduced, and the international standard rabies fixed strain pv-2061 and low generation Vero cells were used. In 2004, the technology was successfully connected, and the industrial production of human rabies vaccine was started, with an annual production scale of more than 8million people. The product was officially launched on May 8, 2005, and the global vaccination has exceeded 6million people

about Liaoning Chengda

Liaoning Chengda Co., Ltd. (hereinafter referred to as "Chengda shares"), was founded in August 1993. In August, 1996, Chengda was listed on the Shanghai Stock Exchange, with a registered capital of 902million yuan. The company is headquartered in Chengda building, No. 71, Renmin Road, Dalian, China. There are more than 8000 employees. Chengda has seven subsidiaries, and Liaoning Chengda biological Co., Ltd., which specializes in biopharmaceutical, is one of its subsidiaries

as of the end of June 2009, the total assets of the company were 7.35 billion yuan; The net assets are 5.7 billion yuan; The total annual trade volume is nearly 6billion yuan; The annual total import and export volume is nearly 400million US dollars; The annual net profit is more than 1 billion yuan

at the same time

note: the reprinted content indicates the source. The reprint is for the purpose of transmitting more information, and does not mean to agree with its views or confirm the authenticity of its content

Copyright © 2011 JIN SHI